Chugai Entered into a License Agreement with Noile-Immune Biotech for PRIME CAR-T Technology
Shots:
- Noile-Immune to receive an up front & technology transfer fee, ~145.6M upon achievement of development or sales milestones & is also eligible to receive royalties upon the successful launch of product using PRIME technology
- Chugai gets the rights to use PRIME technology to develop PRIME CAR-T cells & also obtains the rights to develop, manufacture & commercialize PRIME CAR-T cell products for certain targets
- The collaboration focuses to make CAR-T cell therapy accessible to patients with solid tumors using PRIME & drug discovery technology. The preclinical studies showed that the PRIME technology increases the expression of IL-7 and CCL19 & boosts CAR-T & patients' own immune cells' proliferation & migration into solid tumors
Ref: Chugai | Image: Chugai
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
